|
|
Bristol myers Squibb Company (BMY) |
|
Price: $63.8200
$-0.74 
-1.146%
|
| Day's High:
| $64.97
| Week Perf:
| -3.02 %
|
| Day's Low: |
$ 63.70 |
30 Day Perf: |
-5.61 % |
| Volume (M): |
8,459 |
52 Wk High: |
$ 81.44 |
| Volume (M$): |
$ 539,847 |
52 Wk Avg: |
$72.40 |
| Open: |
$64.51 |
52 Wk Low: |
$63.70 |
|
|
| Market Capitalization (Millions $) |
134,917 |
| Shares
Outstanding (Millions) |
2,114 |
| Employees |
32,200 |
| Revenues (TTM) (Millions $) |
45,848 |
| Net Income (TTM) (Millions $) |
7,329 |
| Cash Flow (TTM) (Millions $) |
-3,531 |
| Capital Exp. (TTM) (Millions $) |
1,143 |
Bristol Myers Squibb Company
Bristol-Myers Squibb Company was incorporated under the laws of the State of Delaware
in August 1933 under the name Bristol-Myers Company, as successor to a New York
business started in 1887. In 1989, Bristol-Myers Company changed its name to Bristol-Myers
Squibb Company as a result of a merger. The Company, through its divisions and
subsidiaries, is engaged in the discovery, development, licensing, manufacturing,
marketing, distribution and sale of pharmaceuticals and other healthcare related
products.
Company Address: 430 E. 29th Street, 14FL New York 10016 NY
Company Phone Number: 546-4200 Stock Exchange / Ticker: NYSE BMY
| BMY is expected to report next financial results on July 26, 2023. |
Next quarterly dividend pay out on August 01, 2023. |
|
|
|
Customers Net Income grew by |
BMY's Customers Net Profit Margin fell to |
8.68 % |
4.26 %
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Q Biomed Inc
For the fourth quarter of 2022 earnings season Q Biomed Inc had turn a round to surplus by exhibiting earnings per share of $0.02 per share compare to $-0.08 a year before and earnings per share turned positive from $-0.03 per share from the prior financial reporting period. The revenue went down sharply by -88.053 % to $0.01 million from $0.10 million in the comparable financial reporting period a year before and sequentially Revenue Tumbled by -52.286 % from $0.03 million.
|
|
23andme Holding Co
23andme Holding Co Posts Mixed Q4 Results, Despite Lower Demand
23andme Holding Co, the popular genetic testing company, has released its latest earnings report for Q4 2023. In a disappointing development for investors, the company's revenue was hit hard by lower demand, leading to a vanishing revenue and higher deficit.
While the earnings report may have been mixed, there was some positive news to report. The company announced that it had been able to decrease its loss per share to $-0.13 per share, which may be seen as an encouraging sign to some investors. However, revenue decreased by -8.137% to $92.38 million, signifying that the company still has some way to go in order to generate more growth.
|
|
Shuttle Pharmaceuticals Holdings Inc
As the earnings season for January to March 31, 2023, continues, many corporations have announced their respective results. The pharmaceutical industry, a significant player in the global market, has also been reporting their earnings. One company that has recently released its earnings report is Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc (SHPH), a rising player in the industry, has issued an operating deficit of $-1.54478 million for the first quarter of the 2023 earnings season. While the shareholders anticipate additional revenue sources to evolve in the near future, they are less interested in the corporation's current accomplishment.
It is not surprising that the company realized a net loss of $-0.975 million, which has extended from $-0.078 million in the financial quarter ending March 31, 2022. The shareholders' expectations of additional revenue streams reflect the investors' desire to see solid growth and profitability in the long run.
However, it is essential to understand that the pharmaceutical industry is highly competitive, which means that many significant companies operate in this space. These companies tend to have diversified product portfolios, expansive distribution networks, and significant marketing budgets, which can help secure their market share and profitability.
It is noteworthy that Shuttle Pharmaceuticals Holdings Inc is a rising player in the pharmaceutical industry, which means that the company is still finding its feet in the market. The most crucial measure of the company's growth and profitability in the long run will stem from the successful development, approval, and commercialization of its pipeline products.
|
|
Bullfrog Ai Holdings Inc
Bullfrog AI Holdings Inc: An Overview
Bullfrog AI Holdings Inc is a pharmaceutical company that specializes in creating innovative drugs using artificial intelligence (AI) technology. The company was founded in 2019, with headquarters located in Toronto, Canada. Bullfrog AI Holdings Inc is focused on developing new drugs for diseases that have no known cure. The company's primary aim is to revolutionize the pharmaceutical industry with its cutting-edge technologies and creative solutions.
The company's technological capabilities come from its emphasis on AI, machine learning, and data analytics. Bullfrog AI Holdings Inc uses AI technology to analyze vast amounts of data to identify drug candidates that have a high likelihood of success in clinical trials. This approach enables the company to produce drugs that are more efficient and effective than traditional drugs.
|
|
Ocean Biomedical Inc
Ocean Biomedical Inc. is a major pharmaceutical preparations company that specializes in developing, manufacturing, and distributing drugs and medical devices. The company has been in operation for several years and has a strong track record within the industry. However, like many companies in the pharmaceutical sector, Ocean Biomedical operates within a highly competitive market, where constantly evolving regulatory environments, technological advancements, and shifting consumer demands can have a significant impact on the company's performance.
In the first quarter of 2023, Ocean Biomedical Inc. faced significant challenges. The company announced a shortfall of $-67.401 million, which was a significant drop from the $0.043 million net income reported in the same period the previous year. The unexpected adjustment in revenue during the January to March 31 2023 reporting cycle caught shareholders off guard. However, investors had been monitoring Ocean Biomedical's operational shortfall, which stood at $-5.223 million during the same period.
|
| Per Share |
Current |
| Earnings (TTM) |
3.43 $ |
| Revenues (TTM) |
21.69 $
|
| Cash Flow (TTM) |
- |
| Cash |
4.38 $
|
| Book Value |
15.08 $
|
| Dividend (TTM) |
2.17 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
3.43 $
|
| Revenues (TTM) |
21.69 $ |
| Cash Flow (TTM) |
- |
| Cash |
4.38 $
|
| Book Value |
15.08 $ |
| Dividend (TTM) |
2.17 $ |
|
|
| |
| Eliquis |
|
Segment |
|
 |
of total Revenue |
| SPRYCEL |
|
Segment |
|
|
of total Revenue |
| ABILIFY |
|
Segment |
|
|
of total Revenue |
| Erbitux |
|
Segment |
|
|
of total Revenue |
| SUSTIVA |
|
Segment |
|
|
of total Revenue |
| BARACLUDE |
|
Segment |
|
|
of total Revenue |
| ORENCIA |
|
Segment |
|
|
of total Revenue |
| Other |
|
Segment |
|
|
of total Revenue |
| Total Pharmaceuticals |
|
Segment |
|
|
of total Revenue |
| |
| |
Company Estimates |
|
| |
• Revenue Outlook
Bristol Myers Squibb announced annual revenue outlook on
• Earnings Outlook
Bristol myers Squibb Company issued annual earnings guidance on
|
|
|
|
|
|
2.26%